NEJM publishes results of ENDEAR study of Spinraza, a new treatment for spinal muscular atrophy.- Biogen + Ionis.

Biogen and Ionis Pharmaceuticals, Inc. announced that the end of study results from ENDEAR, the Phase III study of Spinraza (nusinersen) for the treatment of spinal muscular atrophy were published in The New England Journal of Medicine. Spinraza is the first and only approved treatment for spinal muscular atrophy.

See- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy